Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension

Pharmacology

Volumn 88, Issue 1-2, 2011, Pages 72-81

  Mendizábal, Yolanda ^a   Llorens, Sílvia ^a   Nava, Eduardo ^a  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Endothelium; Glitazones; Hypertension; Resistance arteries

Indexed keywords

ACETYLCHOLINE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CONSTRICTION; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; HEREDITARY HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ACETYLCHOLINE; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; EPINEPHRINE; HYDRAZINES; HYPERTENSION; HYPOGLYCEMIC AGENTS; INDOMETHACIN; MALE; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITROPRUSSIDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; THIAZOLIDINEDIONES; THROMBOXANE A2; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 80051587045     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000330092     Document Type: Article

References (21)

1. Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, Usadel KH, Konrad T: Effects of pioglitazone in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-5506. (Pubitemid 36034352)
2. Asano M, Nakajima T, Iwasawa K, Morita T, Nakamura F, Imuta H, Chisaki K, Yamada N, Omata M, Okuda Y: Troglitazone and pioglitazone attenuate agonist-dependent Ca 2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 1999; 128: 673-683. (Pubitemid 29504759)
3. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ: Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005; 25: 1903-1909. (Pubitemid 41243461)
4. Nomura H, Yamawaki H, Mukohda M, Okada M, Hara Y: Mechanisms underlying pio gli -tazone-mediated relaxation in isolated blood vessel. J Pharmacol Sci 2008; 108: 258-265.
5. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57. (Pubitemid 36091625)
6. Tsukamoto H, Hishinuma T, Suzuki N, Tayama R, Hiratsuka M, Yoshihisa T, Mizugaki M, Goto J: Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. Prostaglandins Other Lipid Mediat 2004; 73: 191-213. (Pubitemid 38757798)
7. Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41: 19-26. (Pubitemid 8132079)
8. Diederich D, Yang ZH, Buhler FR, Luscher TF: Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990; 258:H445-H451. (Pubitemid 20103168)
9. Serne EH, de Jongh RT, Eringa EC, Ijzerman RG, Stehouwer CD: Microvascular dysfunction: A potential pathophysiological role in the metabolic syndrome. Hypertension 2007; 50: 204-211. (Pubitemid 46986042)
10. Brandes RP, Schmitz-Winnenthal FH, Feletou M, Godecke A, Huang PL, Vanhoutte PM, Fleming I, Busse R: An endotheliumderived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci USA 2000; 97: 9747-9752. (Pubitemid 30650847)
11. Xavier F, Blanco-Rivero J, Ferrer M, Balfagon G: Endothelium modulates vasoconstrictor response to prostaglandin I 2 in rat mesenteric resistance arteries: Interaction between EP and TP receptors. Br J Pharmacol 2009; 158: 1787-1795.
12. Llorens S, Mendizabal Y, Nava E: Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension. Eur J Pharmacol 2007; 575: 105-112. (Pubitemid 47576075)
13. Li J, Bukoski RD: Endothelium-dependent relaxation of hypertensive resistance arteries is not impaired under all conditions. Circ Res 1993; 72: 290-296. (Pubitemid 23024517)
14. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J: Secondary prevention of macrovascular events in patients with type 2 dia -betes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289. (Pubitemid 41416583)
15. Petrica L, Petrica M, Vlad A, Dragos JC, Gluhovschi G, Ianculescu C, Dumitrascu V, Giju S, Gluhovschi C, Bob F, Ursoniu S, Gadalean F, Velciov S, Bozdog G, Marian R: Nephro-and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: A randomized controlled trial. Wien Klin Wochenschr 2009; 121: 765-775.
16. Kojima M, Asano M, Aoki K, Yamamoto M, Matsuda T: Decrease in alpha 1-adrenoceptor reserve in mesenteric arteries isolated from spontaneously hypertensive rats. J Hypertens 1989; 7: 873-878. (Pubitemid 20034394)
17. O'Brien SF, McKendrick JD, Radomski MW, Davidge ST, Russell JC: Vascular wall reactivity in conductance and resistance arteries: Differential effects of insulin resistance. Can J Physiol Pharmacol 1998; 76: 72-76. (Pubitemid 28201101)
18. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, Lo Gerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-1862. (Pubitemid 29415208)
19. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A: Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000; 106: 1521-1530. (Pubitemid 32040953)
20. Aubert G, Burnier M, Dulloo A, Perregaux C, Mazzolai L, Pralong F, Zanchi A: Neuroendocrine characterization and anorexigenic effects of telmisartan in diet-and glitazone-induced weight gain. Metabolism 2010; 59: 25-32.
21. Grinsell JW, Lardinois CK, Swislocki A, Gonzalez R, Sare JS, Michaels JR, Starich GH: Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 2000; 13: 370-375. (Pubitemid 30312656)